News & Comments

Why Eli Lilly Wanted Nektar’s Drug NKTR-358 So Badly. Incyte’s Most Recent News

It took only a few months after the dosing stages of NKTR-358 in in a Phase I trial for Eli Lilly to strike a deal worth $400 million with the ascending firm Nektar (NKTR) related to the drug. Eli …

Developing Another Better CAR Using NK Cells Instead of T Cells. Nektar Has Great News

IMPROVING ON CAR IMMUNOTHERAPY APPROACH  When we stated that chimeric antigen receptor CAR immunotherapy process was created to remain and improve, we aimed at demonstrating our conviction that the …

The Meaning of a 10-0 Vote in Favor of Novartis’ CAR T-Cell Therapy Approval.

A BIG YES for Novartis CAR-T product has come from the  Food and Drug Administration (FDA) advisory committee. The committee recommended FDA approval for Novartis product CTL019 for pediatric acute …

 

Today’s Highlights

Amgen Outperformed and Will Continue to Outperform

Amgen’s (AMGN) stock outperformed in the past 6 months for significant reasons and these reasons are still there as we observed listening to the …

Theravance Biopharma Has Good News for COPD Patients

Theravance Biopharma (TBPH) and Mylan N.V. (MYL) announced positive results from a 12-month Phase 3 safety study of revefenacin (TD-4208). The drug …

Vertex: A Cystic Fibrosis Institution with a Bright Future

Yesterday, Wednesday July 19, Vertex’ (VRTX) stock added over 20% to its value, recording a new all time high. Why? On Tuesday the firm …

Arena’s Successful Pulmonary Arterial Hypertension Drug. Novartis CAR-T Product Review for Approval Tomorrow

Arena (ARNA) announced positive Phase 2 clinical trial results for its drug ralinepag1 for pulmonary arterial hypertension (PAH). In the 61-patient …

Our Most Commented Articles:

Amgen Outperformed and Will Continue to Outperform

Amgen’s (AMGN) stock outperformed in the past 6 months for significant reasons and these reasons are still there as we observed listening to the firm’s quarterly results. The firm’s results surpassed analysts’ …

Why Eli Lilly Wanted Nektar’s Drug NKTR-358 So Badly. Incyte’s Most Recent News

It took only a few months after the dosing stages of NKTR-358 in in a Phase I trial for Eli Lilly to strike a deal worth $400 million with the ascending firm Nektar (NKTR) related to the drug. Eli Lilly seemed impressed …

Top